Congratulations go to Business Weekly Awards finalists Tessellate Bio, Laverock Therapeutics and NRG Therapeutics!

We are delighted to reveal that three SBC based occupiers were shortlisted into the final of the 2024 Business Weekly Awards held at Queen’s College, Cambridge, out of a record number of entrants, with some fierce competition.

Tessellate Bio, said: “During the last year we have expanded, opening the doors to our labs in Stevenage Bioscience Catalyst and making significant progress in our aim to become a global leader in precision oncology based on a novel approach to the development of highly targeted treatments for cancer. We are redefining Synthetic Lethality to develop treatments for large, currently unserved patient populations.”

NRG Therapeutics, said: “We’re delighted to be recognised by Business Weekly newspaper for our progress in tackling some of the most important challenges in drug discovery research and human healthcare by leveraging breakthrough science in the field of mitochondrial biology to identify new therapies to treat neurodegenerative disorders such as Parkinson’s and Amyotrophic Lateral Sclerosis (ALS)/Motor Neurone’s Disease (MND).”

Laverock Therapeutics, said: “2023 was a transformational year for Laverock Therapeutics – it saw us take significant steps in advancing our technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of more effective, safer and accessible programmable advanced therapies. We raised the second largest UK life sciences seed round of 2023, at £13.5 million, and grew our team by more than 50% in the past year.”

Read the full article in Business Weekly Newspaper here.

SBC celebrates with occupiers, finalists and industry leaders at Business Weekly Awards 2024.